Chaudhary Kanishk, Ngai Stanley
From the Princess Alexandra Hospital, Woolloongabba, Queensland, Australia.
Clin Nucl Med. 2023 Mar 1;48(3):e115-e117. doi: 10.1097/RLU.0000000000004453. Epub 2022 Oct 21.
We report a case of vertebral osteonecrosis after chemotherapy in a 24-year-old man with non-Hodgkin lymphoma, with transient avidity on 18F-FDG PET initially misinterpreted as recurrent extranodal disease. The patient demonstrated a partial metabolic response on midtreatment restaging PET; however, posttreatment PET showed an increase in uptake in T4 and T5 vertebrae, interpreted as recurrent vertebral disease. Repeat PET performed 9 days later showed resolution of thoracic vertebral uptake without interval treatment. On follow-up PET study, thoracic vertebrae demonstrated photopenia with sclerosis on CT, concerning for osteonecrosis. MRI features were concordant with this diagnosis.
我们报告了一例24岁非霍奇金淋巴瘤男性患者化疗后发生椎体骨坏死的病例,其最初在18F-FDG PET上的短暂摄取活性被误诊为结外疾病复发。该患者在治疗中期重新分期PET上显示出部分代谢反应;然而,治疗后PET显示T4和T5椎体摄取增加,被解释为椎体疾病复发。9天后重复进行的PET显示胸椎摄取消失,期间未进行治疗。在随访PET研究中,胸椎在CT上表现为放射性稀疏伴硬化,提示骨坏死。MRI特征与该诊断一致。